Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second-line Systemic Therapy with or Without Stereotactic Body Radiotherapy (SBRT) for Oligoprogressive Hepatocellular Carcinoma After Standard First-line Systemic Treatment: a Prospective, Randomized, Phase II Study

NCT06592612 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06592612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06592612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second-line Systemic Therapy with or Without Stereotactic Body Radiotherapy (SBRT) for Oligoprogressive Hepatocellular Carcinoma After Standard First-line Systemic Treatment: a Prospective, Randomized, Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2024
Completion date
October 31, 2026
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, oligoprogression